NRA-CANDESARTAN HCTZ 32 MG — DIN 02531267
CANDESARTAN CILEXETIL : 32 MG HYDROCHLOROTHIAZIDE : 25 MG · NORA PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is NRA-CANDESARTAN HCTZ?
NRA-CANDESARTAN HCTZ 32 MG contains CANDESARTAN CILEXETIL : 32 MG HYDROCHLOROTHIAZIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02531267, held by NORA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NRA-CANDESARTAN HCTZ used for?
Treatment of essential hypertension in patients for whom combination therapy is appropriate. Not indicated for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Candersartan And Diuretics in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Candersartan And Diuretics, across 49 DINs, of which 22 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 3 | 3 | AURO-CANDESARTAN HCT | Sourceable in Canada |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 3 | 3 | ATACAND PLUS | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP CANDESARTAN-HCT | Sourceable in Canada |
| NORA PHARMA INC | 3 | 3 | NRA-CANDESARTAN HCTZ | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ CANDESARTAN PLUS | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 2 | CANDESARTAN/HCTZ | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 2 | TEVA-CANDESARTAN/HCTZ | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-CANDESARTAN-HCTZ | Sourceable in Canada |
| PRO DOC LIMITEE | 1 | 1 | CANDESARTAN-HCTZ | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 1 | 1 | CANDESARTAN HCT | Sourceable in Canada |
| ACCEL PHARMA INC | 3 | 0 | ACCEL-CANDESARTAN/HCTZ | No marketed DIN |
| ALEMBIC PHARMACEUTICALS LIMITED | 3 | 0 | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 32 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 30, 100, or 1000 tablets; Blister packs of 30 or 80 tablets. |
| Storage | Not explicitly stated in the provided text (section 11 is listed in TOC but content is missing), though typically room temperature. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Candersartan And Diuretics |
|---|---|
| ATC code | C09DA06 |
| AHFS class | 24:32.08 ; 40:28.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02531267 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2531267 |
| Brand name | NRA-CANDESARTAN HCTZ |
| Generic / active ingredient | CANDESARTAN CILEXETIL : 32 MG HYDROCHLOROTHIAZIDE : 25 MG |
| Market authorization holder | NORA PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | C09DA06 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09DA |
| Current status | MARKETED |
| Status date | 20-Jul-2023 |
| Original market date | 2023-07-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualized by titration of components. Once stabilized, take one tablet daily at the same time, with or without food. Not for initial therapy.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ingredients or sulfonamides; anuria; pregnancy; nursing; children <1 year; combination with aliskiren in diabetes/renal impairment; severe hepatic/renal impairment; gout.
Warnings and precautions
Fetal toxicity; dual blockade of RAS; hypotension; non-melanoma skin cancer risk; electrolyte imbalance; systemic lupus erythematosus exacerbation; acute myopia/glaucoma.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
22 of 49 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ATACAND PLUS | 12.5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 02332922 |
| ATACAND PLUS | 25 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 02332957 |
| ATACAND PLUS | 12.5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 02244021 |
| AURO-CANDESARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | 02421046 |
| AURO-CANDESARTAN HCT | 25 MG | TABLET | AURO PHARMA INC | MARKETED | 02421054 |
| AURO-CANDESARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | 02421038 |
| CANDESARTAN HCT | 16 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02394812 |
| CANDESARTAN-HCTZ | 16.0 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02392275 |
| CANDESARTAN/HCTZ | 16 MG | TABLET | SANIS HEALTH INC | MARKETED | 02394804 |
| CANDESARTAN/HCTZ | 32 MG | TABLET | SANIS HEALTH INC | MARKETED | 02536064 |
2 · Same class — other molecules in ATC C09DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valsartan And Diuretics | APO-VALSARTAN/HCTZ · AURO-VALSARTAN HCT · AVA-VALSARTAN HCT · DIOVAN-HCT · +8 more | 63 | 32 | Yes |
| Candersartan And Diuretics | ACCEL-CANDESARTAN/HCTZ · ACT CANDESARTAN/HCT · AG-CANDESARTAN HCT · APO-CANDESARTAN/HCTZ · +16 more | 49 | 22 | Yes |
| Telmisartan And Diuretics | ACH-TELMISARTAN HCTZ · ACT TELMISARTAN/HCT · AG TELMISARTAN-HCT · ALEMBIC-TELMISARTAN/HCTZ · +17 more | 42 | 22 | Yes |
| Losartan And Diuretics | ACT LOSARTAN/HCT · AG-LOSARTAN HCTZ · APO-LOSARTAN/HCTZ · AURO-LOSARTAN HCT · +19 more | 53 | 21 | Yes |
| Olmesartan Medoxomil And Diuretics | ACH-OLMESARTAN HCTZ · AG-OLMESARTAN HCTZ · APO-OLMESARTAN/HCTZ · AURO-OLMESARTAN HCTZ · +11 more | 45 | 21 | Yes |
| Irbesartan And Diuretics | ACT IRBESARTAN/HCT · AG-IRBESARTAN HCTZ · APO-IRBESARTAN/HCTZ · AURO-IRBESARTAN HCT · +19 more | 67 | 17 | Yes |
| Azilsartant Medoximil And Diuretics | EDARBYCLOR | 3 | 2 | Yes |
| Eprosartan And Diuretics | TEVETEN PLUS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C09D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C09DB | Telmisartan And Amlodipine | 12 | 8 |
| C09DX | Valsartan And Sacubitril | 6 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.